Pharmacology and Physiology Department, The George Washington University, 2300 Eye Street, Washington, DC 20037, USA.
Stem Cell Rev Rep. 2011 Jun;7(2):315-25. doi: 10.1007/s12015-010-9202-x.
Repair of damaged myocardium with pluripotent stem cell derived cardiomyocytes is becoming increasingly more feasible. Developments in stem cell research emphasize the need to address the foreseeable problem of immune rejection following transplantation. Pluripotent stem cell (PSC) derived cardiomyocytes have unique immune characteristics, some of which are not advantageous for transplantation. Here we review the possible mechanisms of PSC-derived cardiomyocytes rejection, summarize the current knowledge pertaining to immunogenicity of such cells and describe the existing controversies. Myocardial graft rejection can be reduced by modifying PSCs prior to their differentiation into cardiomyocytes. Overall, this approach facilitates the development of universal donor stem cells suitable for the regeneration of many different tissue types.
用多能干细胞衍生的心肌细胞修复受损的心肌变得越来越可行。干细胞研究的发展强调了需要解决移植后可预见的免疫排斥问题。多能干细胞（PSC）衍生的心肌细胞具有独特的免疫特性，其中一些特性不利于移植。在这里，我们回顾了 PSC 衍生的心肌细胞排斥的可能机制，总结了目前关于此类细胞免疫原性的知识，并描述了现有的争议。通过在 PSC 分化为心肌细胞之前对其进行修饰，可以减少心肌移植物的排斥。总的来说，这种方法促进了通用供体干细胞的发展，适用于许多不同组织类型的再生。
